MARKET

RLMD

RLMD

Relmada Therapeutics Inc
NASDAQ
0.2898
-0.0022
-0.75%
After Hours: 0.3000 +0.0102 +3.52% 18:46 04/17 EDT
OPEN
0.2903
PREV CLOSE
0.2920
HIGH
0.3156
LOW
0.2830
VOLUME
113.99K
TURNOVER
--
52 WEEK HIGH
4.730
52 WEEK LOW
0.2404
MARKET CAP
9.62M
P/E (TTM)
-0.1093
1D
5D
1M
3M
1Y
5Y
1D
Relmada Therapeutics To Present NDV-01 Data at American Urology Association On April 28, 2025
Benzinga · 6d ago
Weekly Report: what happened at RLMD last week (0407-0411)?
Weekly Report · 6d ago
Relmada Therapeutics To Present NDV-01 Data at AUA2025
Barchart · 6d ago
Weekly Report: what happened at RLMD last week (0331-0404)?
Weekly Report · 04/07 09:17
Weekly Report: what happened at RLMD last week (0324-0328)?
Weekly Report · 03/31 09:20
Relmada Therapeutics: Hold Rating Amid Uncertainty and Strategic Shifts
TipRanks · 03/31 06:17
Relmada Therapeutics: Strategic Acquisitions and Pipeline Progress
TipRanks · 03/29 00:09
Relmada Therapeutics Reports 2024 Financial Results and Strategic Progress
TipRanks · 03/28 03:56
More
About RLMD
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for central nervous system (CNS) and metabolic disorders. The Company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Esmethadone, an isomer of methadone, is a new chemical entity (NCE) that potentially addresses areas of high unmet medical need in the treatment of CNS diseases and other disorders. The Company’s lead program, REL-1017, is a NCE and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. Its lead product candidate, esmethadone, is being developed as a rapidly acting, oral agent for the treatment of depression and other potential indications. Sepranolone is its phase IIb ready neurosteroid developed for the potential treatment of Tourette syndrome and other compulsive disorders.

Webull offers Relmada Therapeutics Inc stock information, including NASDAQ: RLMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RLMD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RLMD stock methods without spending real money on the virtual paper trading platform.